HuveGuard MMAT Suspension for Oral Suspension for Chickens

Summary of Product characteristics

                                Revised: September 2020
AN: 02196/2019
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
HuveGuard
MMAT suspension for oral suspension for chickens
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose of 0.025 ml contains:
ACTIVE SUBSTANCES:
Sporulated oocysts derived from attenuated precocious strains of
_Eimeria_ species:
_Eimeria acervulina_, strain RA 3+20
50 -139 oocysts*
_Eimeria_ _maxima_,_ _strain MCK+10
100 -278 oocysts*
_Eimeria mitis_,_ _strain Jormit 3+9
100 -278 oocysts*
_Eimeria tenella_, strain Rt 3 +15
150 -417 oocysts*
*According to the _in vitro_ counting procedure of the manufacturer at
the time of
blending and at release.
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for oral suspension.
Colourless to white to light beige suspension when shaken.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Chickens.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of chickens to reduce infection and
clinical signs of
coccidiosis caused by_ E. acervulina, E. maxima, E. mitis _and_ E.
tenella._
Onset of immunity: 21 days post vaccination.
Duration of immunity: not demonstrated.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
Revised: September 2020
AN: 02196/2019
Page 2 of 6
The vaccine contains live coccidian oocysts and is dependent upon
replication of the
vaccinal strains within the chickens for building up of immunity.
It is common to find oocysts in the gastro-intestinal tract of
vaccinated birds from 1-3
weeks or more after vaccination. These oocysts are most likely to be
vaccinal
oocysts which recycle in the birds via the litter. Recycling of
oocysts is necessary for
the development of immunity and for continued protection.
Since the protection against coccidial infection following vaccination
is enhanced by
natural challenge, access to any therapeutic agents having
anti-coccidial activity at
any time following vaccination can a
                                
                                Read the complete document